Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | C5AR1 | P21730 | 3/20 | 0.41 |
| ▸ | F12 | P00748 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.39 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.38 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | PARP1 | P09874 | 1/20 | 0.37 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.37 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15333088 | 0.82 | C5AR1 (0.46) | C5AR1F12MAPTESR2ADORA1 | |
| SCHEMBL31163741 | 0.81 | C5AR1 (0.43) | C5AR1F12MAPTESR2ADORA1 | |
| SCHEMBL31586458 | 0.81 | C5AR1 (0.43) | C5AR1F12MAPTESR2ADORA1 | |
| SCHEMBL16210129 | 0.78 | DDB1 (0.41) | C5AR1MAPTESR2ADORA1NR1H2 | |
| SCHEMBL26623021 | 0.77 | C5AR1 (0.41) | C5AR1F12MAPTESR2ADORA1 | |
| SCHEMBL22727600 | 0.77 | C5AR1 (0.39) | C5AR1F12MAPTESR2ADORA1 | |
| SCHEMBL16210205 | 0.76 | MAPT (0.40) | C5AR1F12MAPTESR2ADORA1 | |
| SCHEMBL31163742 | 0.75 | C5AR1 (0.55) | C5AR1F12MAPTESR2NR1H2 | |
| SCHEMBL31163760 | 0.74 | ESR2 (0.46) | C5AR1F12MAPTESR2ADORA1 | |
| SCHEMBL16220624 | 0.73 | C5AR1 (0.46) | C5AR1F12MAPTESR2ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2991989-B1 | IMIDAZO-TRIAZINE DERIVATIVES AS PDE10 INHIBITORS | PFIZER (US) | 2017-06-28 | — | — | EP | disclosed |
| EP-2991989-B1 | IMIDAZO-TRIAZINE DERIVATIVES AS PDE10 INHIBITORS | PFIZER (US) | 2017-06-28 | — | — | EP | disclosed |
| US-9296761-B2 | Triazine derivatives | PFIZER INC. (US) | 2016-03-29 | — | — | US | disclosed |
| US-9296761-B2 | Triazine derivatives | PFIZER INC. (US) | 2016-03-29 | — | — | US | disclosed |
| US-9296761-B2 | Triazine derivatives | PFIZER INC. (US) | 2016-03-29 | — | — | US | disclosed |
| US-20150353579-A1 | Triazine Derivatives | PFIZER (US) | 2015-12-10 | — | — | US | disclosed |
| US-20150353579-A1 | Triazine Derivatives | PFIZER (US) | 2015-12-10 | — | — | US | disclosed |
| US-20150353579-A1 | Triazine Derivatives | PFIZER (US) | 2015-12-10 | — | — | US | disclosed |
| US-9145427-B2 | Triazine derivatives | PFIZER INC. (US) | 2015-09-29 | — | — | US | disclosed |
| US-9145427-B2 | Triazine derivatives | PFIZER INC. (US) | 2015-09-29 | — | — | US | disclosed |
| US-20150080401-A1 | Triazine Derivatives | PFIZER (US) | 2015-03-19 | — | — | US | disclosed |
| US-20150080401-A1 | Triazine Derivatives | PFIZER (US) | 2015-03-19 | — | — | US | disclosed |
| US-20150080401-A1 | Triazine Derivatives | PFIZER (US) | 2015-03-19 | — | — | US | disclosed |
| US-8933224-B2 | Triazine derivatives | PFIZER INC. (US) | 2015-01-13 | — | — | US | disclosed |
| US-8933224-B2 | Triazine derivatives | PFIZER INC. (US) | 2015-01-13 | — | — | US | disclosed |
| US-8933224-B2 | Triazine derivatives | PFIZER INC. (US) | 2015-01-13 | — | — | US | disclosed |
| US-20140329820-A1 | Triazine Derivatives | PFIZER INC. (US) | 2014-11-06 | — | — | US | disclosed |
| WO-2014177977-A1 | IMIDAZO-TRIAZINE DERIVATIVES AS PDE10 INHIBITORS | PFIZER INC. (US) | 2014-11-06 | — | — | WO | disclosed |
| US-20140329820-A1 | Triazine Derivatives | PFIZER INC. (US) | 2014-11-06 | — | — | US | disclosed |
| US-20140329820-A1 | Triazine Derivatives | PFIZER INC. (US) | 2014-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140329820-A1 | Triazine Derivatives | PDE12, PDE5A, PDE10A | C5AR1 1628/4885F12 327/4885MAPT 3633/4885 |
| US-20150353579-A1 | Triazine Derivatives | PDE12, PDE5A, PDE10A | C5AR1 1628/4885F12 327/4885MAPT 3633/4885 |
| US-20150080401-A1 | Triazine Derivatives | PDE12, PDE5A, PDE10A | C5AR1 1628/4885F12 327/4885MAPT 3633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.